Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG)
Carolyn Nessim(University of Ottawa), Guy Lahat(Tel Aviv University), Yvonne Schrage(The Netherlands Cancer Institute), Carol J. Swallow(University Health Network), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Vittorio Quagliuolo(Humanitas University), Venu G. Pillarisetty(University of Washington), Kenneth Cardona(Emory University), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Rosalba Miceli(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonino De Paoli(Centro di Riferimento Oncologico), Giovanni Grignani(Candiolo Cancer Institute), Francesco Barretta(Fondazione IRCCS Istituto Nazionale dei Tumori), Chandrajit P. Raut(Dana-Farber Cancer Institute), D. Strauß(Royal Marsden Hospital), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Robert J. Canter(Virginia Tech), Winan J. van Houdt(Diakonessenhuis hospital), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Sanjay P. Bagaria(WinnMed), Eberhard Stoeckle(Institut Bergonié), Nita Ahuja(Johns Hopkins University), John T. Mullen(Massachusetts General Hospital), Ricardo González(Moffitt Cancer Center), Elisabetta Pennacchioli(European Institute of Oncology), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 41
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k